Mekinist 0.5 mg Tablets Mekinist contains Trametinib, a reversible, highly selective allosteric inhibitor of mitogen-activated extracellular signal-regulated kinase 1 (MEK1) and MEK2. It blocks MEK activity and cellular proliferation driven by the MAPK pathway. It is indicated, typically in combination with Dabrafenib, for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations, metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation, and advanced BRAF V600E-mutated anaplastic thyroid cancer.